Drug intelligence / Profile preview

ECMT-154

Development stage: Unknown
Lead developer: Manuka Bioscience
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Topical

Overview

ECMT-154 is a topical emollient cream containing 2% mānuka oil, an extract derived from the New Zealand mānuka tree (*Leptospermum scoparium*). Developed by Manuka Bioscience, it is being investigated as a steroid-sparing therapeutic option for the treatment of moderate-to-severe eczema (atopic dermatitis). The product leverages the natural anti-inflammatory and antimicrobial properties of mānuka oil to reduce skin inflammation and manage the skin microbiome. It has been evaluated in multicentre randomized controlled trials in both adult and pediatric populations (ages 2–12) in New Zealand.

Brand names: ECMT-154ECMT154ECMT 154
Other names: 2% mānuka oil cream

Beyond the preview

Go deeper on ECMT-154.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ECMT-154.

Explore the full profile